News

News

POLYNEURON AWARDED GRANT OF CHF 1.2M

By

05.05.2021
Polyneuron Pharmaceuticals AG, a clinical-stage developer of a new class of antigen-specific polymers for the treatment of patients with serious autoimmune diseases, today announced that the company and collaborators at the University of Basel have received a grant from the Swiss Innovation Agency Innosuisse to support a project valued at CHF 1.2 million.